RLYB vs. YS, IFRX, VTVT, SCYX, LABP, ASMB, LTRN, SLS, DERM, and ANEB
Should you be buying Rallybio stock or one of its competitors? The main competitors of Rallybio include YS Biopharma (YS), InflaRx (IFRX), vTv Therapeutics (VTVT), SCYNEXIS (SCYX), Landos Biopharma (LABP), Assembly Biosciences (ASMB), Lantern Pharma (LTRN), SELLAS Life Sciences Group (SLS), Journey Medical (DERM), and Anebulo Pharmaceuticals (ANEB). These companies are all part of the "pharmaceutical preparations" industry.
YS Biopharma (NASDAQ:YS) and Rallybio (NASDAQ:RLYB) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their analyst recommendations, earnings, valuation, dividends, community ranking, media sentiment, risk, profitability and institutional ownership.
Rallybio's return on equity of 0.00% beat YS Biopharma's return on equity.
YS Biopharma has higher revenue and earnings than Rallybio.
YS Biopharma has a beta of 0.51, indicating that its stock price is 49% less volatile than the S&P 500. Comparatively, Rallybio has a beta of -1.63, indicating that its stock price is 263% less volatile than the S&P 500.
Rallybio received 32 more outperform votes than YS Biopharma when rated by MarketBeat users. However, 100.00% of users gave YS Biopharma an outperform vote while only 75.00% of users gave Rallybio an outperform vote.
YS Biopharma currently has a consensus price target of $5.25, suggesting a potential upside of 441.24%. Rallybio has a consensus price target of $12.20, suggesting a potential upside of 566.67%. Given YS Biopharma's higher possible upside, analysts plainly believe Rallybio is more favorable than YS Biopharma.
In the previous week, Rallybio had 4 more articles in the media than YS Biopharma. MarketBeat recorded 9 mentions for Rallybio and 5 mentions for YS Biopharma. Rallybio's average media sentiment score of 1.24 beat YS Biopharma's score of 0.69 indicating that YS Biopharma is being referred to more favorably in the media.
52.6% of YS Biopharma shares are held by institutional investors. Comparatively, 90.3% of Rallybio shares are held by institutional investors. 7.4% of Rallybio shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
YS Biopharma beats Rallybio on 8 of the 14 factors compared between the two stocks.
Get Rallybio News Delivered to You Automatically
Sign up to receive the latest news and ratings for RLYB and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding RLYB and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Rallybio Competitors List
Related Companies and Tools
